Analysis of the efficacy, role and clinical indications of Eltrombopag (Revlan)

Eltrombopag (trade name Revolade) is an oral small molecule thrombopoietin receptor agonist (TPO-RA), which binds to the thrombopoietin receptor ( >c-Mpl receptor) binds to the transmembrane region and activates the JAK/STAT signaling pathway, thereby promoting the proliferation and differentiation of megakaryocytes in the bone marrow, and ultimately increasing the number of peripheral blood platelets. Different from traditional platelet transfusion or immunosuppressive treatment, eltrombopag directly acts on the source of platelet production, can increase platelet levels in a short period of time, and platelets can gradually return to baseline after drug withdrawal.

Eltrombopag was initially approved for the treatment of patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), particularly those who have failed to respond to glucocorticoids, immunoglobulins, or splenectomy. The indications were subsequently expanded to include severe aplastic anemia (SAA), especially in patients with poor response to immunosuppressive therapy (ATG+cyclosporine). It can significantly improve hematopoietic function. In addition, eltrombopag is also used in patients with chronic hepatitis C who develop thrombocytopenia after interferon treatment to help patients maintain the antiviral treatment process. Some studies are also exploring its potential in myelodysplastic syndrome (MDS) and chemotherapy-associated thrombocytopenia.

Multiple clinical studies have confirmed that eltrombopag can significantly increase platelet count in ITP patients within 2 weeks, making 70%of patients achieve clinical response; in SAA patients, its use can not only increase platelets, but also promote the recovery of erythroid and leukocyte cells, showing a multi-lineage hematopoietic stimulation effect. In chronic hepatitis C-related thrombocytopenia, eltrombopag helps approximately 90% of patients successfully complete antiviral treatment. Overall, the drug has definite efficacy, rapid onset of action and high compliance, providing a new treatment approach for a variety of refractory thrombocytopenic diseases.

Although eltrombopag is highly effective, liver function and thrombotic risk still need to be monitored during use. Studies have found that the drug can cause a transient increase in ALT or AST, and some patients need to reduce the dose or temporarily discontinue the drug; when platelets are excessively elevated, there is a risk of venous or arterial thrombosis, so the dose needs to be adjusted strictly in accordance with medical advice. It should also be noted that eltrombopag can chelate with polyvalent cations (such as calcium, iron, and magnesium) in food. It is recommended to take it on an empty stomach or two hours before and after eating dairy products or mineral supplements. Overall, eltrombopag provides an important targeted treatment option for thrombocytopenic diseases, but its use should be under the guidance of a hematologist to ensure a balance between efficacy and safety.

Reference materials:https://www.drugs.com/